Aldeyra Therapeutics Inc. (ALDX)’s Financial Results Comparing With Aduro BioTech Inc. (NASDAQ:ADRO)

Both Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Aduro BioTech Inc. (NASDAQ:ADRO) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aldeyra Therapeutics Inc. 8 0.00 N/A -1.81 0.00
Aduro BioTech Inc. 3 8.78 N/A -1.23 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Aldeyra Therapeutics Inc. and Aduro BioTech Inc.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics Inc. 0.00% -74.8% -65.1%
Aduro BioTech Inc. 0.00% -66.5% -26.3%

Risk and Volatility

Aldeyra Therapeutics Inc. has a 0.75 beta, while its volatility is 25.00% which is less volatile than Standard & Poor’s 500. Competitively, Aduro BioTech Inc.’s 108.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.08 beta.


The Current Ratio and a Quick Ratio of Aldeyra Therapeutics Inc. are 11.2 and 11.2. Competitively, Aduro BioTech Inc. has 9.1 and 9.1 for Current and Quick Ratio. Aldeyra Therapeutics Inc.’s better ability to pay short and long-term obligations than Aduro BioTech Inc.

Analyst Recommendations

Aldeyra Therapeutics Inc. and Aduro BioTech Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aldeyra Therapeutics Inc. 0 0 2 3.00
Aduro BioTech Inc. 0 0 1 3.00

The upside potential is 554.21% for Aldeyra Therapeutics Inc. with consensus price target of $35. Meanwhile, Aduro BioTech Inc.’s consensus price target is $7, while its potential upside is 414.71%. Based on the analysts opinion we can conclude, Aldeyra Therapeutics Inc. is looking more favorable than Aduro BioTech Inc.

Institutional & Insider Ownership

The shares of both Aldeyra Therapeutics Inc. and Aduro BioTech Inc. are owned by institutional investors at 72.9% and 44.1% respectively. Insiders owned 2.2% of Aldeyra Therapeutics Inc. shares. Competitively, Aduro BioTech Inc. has 1.1% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aldeyra Therapeutics Inc. -7.02% -7.83% -10.28% -29.73% -14.22% -10.6%
Aduro BioTech Inc. -5.75% -6.55% -8.38% -9.64% -60.95% 24.24%

For the past year Aldeyra Therapeutics Inc. has -10.6% weaker performance while Aduro BioTech Inc. has 24.24% stronger performance.


Aduro BioTech Inc. beats on 5 of the 8 factors Aldeyra Therapeutics Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.